Cargando…

Two Hits for Bone Regeneration in Aged Patients: Vertebral Bone Marrow Clot as a Biological Scaffold and Powerful Source of Mesenchymal Stem Cells

Recently, the use of a new formulation of bone marrow aspirate (BMA), the BMA clot, has been described. This product entails a naturally formed clot from the harvested bone marrow, which retains all the BMA components preserved in a matrix biologically molded by the clot. Even though its beneficial...

Descripción completa

Detalles Bibliográficos
Autores principales: Salamanna, Francesca, Contartese, Deyanira, Borsari, Veronica, Pagani, Stefania, Barbanti Brodano, Giovanni, Griffoni, Cristiana, Ricci, Alessandro, Gasbarrini, Alessandro, Fini, Milena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804319/
https://www.ncbi.nlm.nih.gov/pubmed/35118056
http://dx.doi.org/10.3389/fbioe.2021.807679
_version_ 1784643051110531072
author Salamanna, Francesca
Contartese, Deyanira
Borsari, Veronica
Pagani, Stefania
Barbanti Brodano, Giovanni
Griffoni, Cristiana
Ricci, Alessandro
Gasbarrini, Alessandro
Fini, Milena
author_facet Salamanna, Francesca
Contartese, Deyanira
Borsari, Veronica
Pagani, Stefania
Barbanti Brodano, Giovanni
Griffoni, Cristiana
Ricci, Alessandro
Gasbarrini, Alessandro
Fini, Milena
author_sort Salamanna, Francesca
collection PubMed
description Recently, the use of a new formulation of bone marrow aspirate (BMA), the BMA clot, has been described. This product entails a naturally formed clot from the harvested bone marrow, which retains all the BMA components preserved in a matrix biologically molded by the clot. Even though its beneficial effects were demonstrated by some studies, the impact of aging and aging-associated processes on biological properties and the effect of BMA cell-based therapy are currently unknown. The purpose of our study was to compare selected parameters and properties of clotted BMA and BMA-derived mesenchymal stem cells (MSCs) from younger (<45 years) and older (>65 years) female donors. Clotted BMA growth factors (GFs) expression, MSCs morphology and viability, doubling time, surface marker expression, clonogenic potential, three-lineage differentiation, senescence-associated factors, and Klotho synthesis from younger and older donors were analyzed. Results indicated that donor age does not affect tissue-specific BMA clot regenerative properties such as GFs expression and MSCs morphology, viability, doubling time, surface antigens expression, colony-forming units, osteogenic and adipogenic differentiation, and Klotho and senescence-associated gene expression. Only few differences, i.e., increased platelet-derived growth factor-AB (PDGF-AB) synthesis and MSCs Aggrecan (ACAN) expression, were detected in younger donors in comparison with older ones. However, these differences do not interfere with all the other BMA clot biological properties. These results demonstrated that BMA clot can be applied easily, without any sample processing and avoiding potential contamination risks as well as losing cell viability, proliferation, and differentiation ability, for autologous transplantation in aged patients. The vertebral BMA clot showed two successful hits since it works as a biological scaffold and as a powerful source of mesenchymal stem cells, thus representing a novel and advanced therapeutic alternative for the treatment of orthopedic injuries.
format Online
Article
Text
id pubmed-8804319
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88043192022-02-02 Two Hits for Bone Regeneration in Aged Patients: Vertebral Bone Marrow Clot as a Biological Scaffold and Powerful Source of Mesenchymal Stem Cells Salamanna, Francesca Contartese, Deyanira Borsari, Veronica Pagani, Stefania Barbanti Brodano, Giovanni Griffoni, Cristiana Ricci, Alessandro Gasbarrini, Alessandro Fini, Milena Front Bioeng Biotechnol Bioengineering and Biotechnology Recently, the use of a new formulation of bone marrow aspirate (BMA), the BMA clot, has been described. This product entails a naturally formed clot from the harvested bone marrow, which retains all the BMA components preserved in a matrix biologically molded by the clot. Even though its beneficial effects were demonstrated by some studies, the impact of aging and aging-associated processes on biological properties and the effect of BMA cell-based therapy are currently unknown. The purpose of our study was to compare selected parameters and properties of clotted BMA and BMA-derived mesenchymal stem cells (MSCs) from younger (<45 years) and older (>65 years) female donors. Clotted BMA growth factors (GFs) expression, MSCs morphology and viability, doubling time, surface marker expression, clonogenic potential, three-lineage differentiation, senescence-associated factors, and Klotho synthesis from younger and older donors were analyzed. Results indicated that donor age does not affect tissue-specific BMA clot regenerative properties such as GFs expression and MSCs morphology, viability, doubling time, surface antigens expression, colony-forming units, osteogenic and adipogenic differentiation, and Klotho and senescence-associated gene expression. Only few differences, i.e., increased platelet-derived growth factor-AB (PDGF-AB) synthesis and MSCs Aggrecan (ACAN) expression, were detected in younger donors in comparison with older ones. However, these differences do not interfere with all the other BMA clot biological properties. These results demonstrated that BMA clot can be applied easily, without any sample processing and avoiding potential contamination risks as well as losing cell viability, proliferation, and differentiation ability, for autologous transplantation in aged patients. The vertebral BMA clot showed two successful hits since it works as a biological scaffold and as a powerful source of mesenchymal stem cells, thus representing a novel and advanced therapeutic alternative for the treatment of orthopedic injuries. Frontiers Media S.A. 2022-01-18 /pmc/articles/PMC8804319/ /pubmed/35118056 http://dx.doi.org/10.3389/fbioe.2021.807679 Text en Copyright © 2022 Salamanna, Contartese, Borsari, Pagani, Barbanti Brodano, Griffoni, Ricci, Gasbarrini and Fini. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Salamanna, Francesca
Contartese, Deyanira
Borsari, Veronica
Pagani, Stefania
Barbanti Brodano, Giovanni
Griffoni, Cristiana
Ricci, Alessandro
Gasbarrini, Alessandro
Fini, Milena
Two Hits for Bone Regeneration in Aged Patients: Vertebral Bone Marrow Clot as a Biological Scaffold and Powerful Source of Mesenchymal Stem Cells
title Two Hits for Bone Regeneration in Aged Patients: Vertebral Bone Marrow Clot as a Biological Scaffold and Powerful Source of Mesenchymal Stem Cells
title_full Two Hits for Bone Regeneration in Aged Patients: Vertebral Bone Marrow Clot as a Biological Scaffold and Powerful Source of Mesenchymal Stem Cells
title_fullStr Two Hits for Bone Regeneration in Aged Patients: Vertebral Bone Marrow Clot as a Biological Scaffold and Powerful Source of Mesenchymal Stem Cells
title_full_unstemmed Two Hits for Bone Regeneration in Aged Patients: Vertebral Bone Marrow Clot as a Biological Scaffold and Powerful Source of Mesenchymal Stem Cells
title_short Two Hits for Bone Regeneration in Aged Patients: Vertebral Bone Marrow Clot as a Biological Scaffold and Powerful Source of Mesenchymal Stem Cells
title_sort two hits for bone regeneration in aged patients: vertebral bone marrow clot as a biological scaffold and powerful source of mesenchymal stem cells
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804319/
https://www.ncbi.nlm.nih.gov/pubmed/35118056
http://dx.doi.org/10.3389/fbioe.2021.807679
work_keys_str_mv AT salamannafrancesca twohitsforboneregenerationinagedpatientsvertebralbonemarrowclotasabiologicalscaffoldandpowerfulsourceofmesenchymalstemcells
AT contartesedeyanira twohitsforboneregenerationinagedpatientsvertebralbonemarrowclotasabiologicalscaffoldandpowerfulsourceofmesenchymalstemcells
AT borsariveronica twohitsforboneregenerationinagedpatientsvertebralbonemarrowclotasabiologicalscaffoldandpowerfulsourceofmesenchymalstemcells
AT paganistefania twohitsforboneregenerationinagedpatientsvertebralbonemarrowclotasabiologicalscaffoldandpowerfulsourceofmesenchymalstemcells
AT barbantibrodanogiovanni twohitsforboneregenerationinagedpatientsvertebralbonemarrowclotasabiologicalscaffoldandpowerfulsourceofmesenchymalstemcells
AT griffonicristiana twohitsforboneregenerationinagedpatientsvertebralbonemarrowclotasabiologicalscaffoldandpowerfulsourceofmesenchymalstemcells
AT riccialessandro twohitsforboneregenerationinagedpatientsvertebralbonemarrowclotasabiologicalscaffoldandpowerfulsourceofmesenchymalstemcells
AT gasbarrinialessandro twohitsforboneregenerationinagedpatientsvertebralbonemarrowclotasabiologicalscaffoldandpowerfulsourceofmesenchymalstemcells
AT finimilena twohitsforboneregenerationinagedpatientsvertebralbonemarrowclotasabiologicalscaffoldandpowerfulsourceofmesenchymalstemcells